T1	Participants 603 678	patients with bone metastases from tumors poorly responsive to chemotherapy
T2	Participants 784 985	Sixty-six patients with poorly responsive tumors such as non-small cell lung cancer (NSCLC), bladder cancer, gastrointestinal cancers, kidney cancer, melanoma and metastatic carcinoma of unknown origin
T3	Participants 1301 1320	66 patients enrolle
